TrianglePartial Oncolysis (NCT06533644)
Partial Oncolysis trial for Metastatic Castration-resistant Prostate Cancer (NCT06533644). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with advanced or metastatic castration-resistant prostate adenocarcinoma progressing after androgen-pathway treatment. Other meaningful treatment options must be unavailable or declined. An accessible tumor is required.
The idea: freezing destroys part of a tumor, followed by SV-102 infusion directly into it. Researchers first increase dose levels, then randomly compare selected doses. Biopsies are required. The study measures safety, tolerated dose, and tumor response. Visceral metastases other than lung metastases exclude participation.
This phase 2 study plans 91 patients. Syncromune sponsors it; fourteen US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.